Latest Glioma Stories
- Live Presentation with Audio Webcast on Tuesday, March 10th at 5:00 p.m. Pacific Time / 8:00 p.m.
Industry and Academic Leader Co-Founded Several Successful Biotechnology Companies, Including Alnylam, Cubist and Alkermes SAN DIEGO, Feb.
- Updated Phase I/II clinical trial data on the maximum tolerated dose for VAL-083 in the treatment of glioblastoma multiforme (GBM) to be presented - VANCOUVER, British Columbia
RnRMarketResearch.com adds “Oligodendroglioma – Pipeline Review, H2 2014” report to its store.
RnRMarketResearch.com adds “Malignant Glioma – Pipeline Review, H1 2015” report to its store.
- Management to host live investor conference call and webcast on February 17, 2015 at 1:30 PM PST - VANCOUVER, British Columbia and MENLO PARK, Calif., Feb.
CALGARY, Feb. 9, 2015 /PRNewswire/ - Oncolytics Biotech Inc.
-- Increases Total Number of DelMar Patents Covering VAL-083 to Three US Patents and One International Patent -- VANCOUVER, British Columbia and MENLO PARK, Calif., Jan.
BUFFALO, N.Y., Dec.
- A handkerchief.
- In general, any miraculous portrait of Christ.